SCHEMBL8248751

SCHEMBL8248751

COC1=C(OC)C(=O)C(C(C)C)=C(C)C1=O

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
IDO1 P14902 2/20 0.48
CDC25A P30304 3/20 0.43
CDC25B P30305 3/20 0.43
MAPT P10636 5/20 0.43
TDP1 Q9NUW8 4/20 0.43
ALDH1A1 P00352 4/20 0.43
LMNA P02545 3/20 0.43
CYP3A4 P08684 2/20 0.43
CYP2D6 P10635 2/20 0.43
CYP2C9 P11712 2/20 0.43
CYP2C19 P33261 2/20 0.43
KDM4E B2RXH2 2/20 0.43
POLB P06746 2/20 0.43
RAB9A P51151 2/20 0.43
SMN1; SMN2 Q16637 2/20 0.43
MAP2K7 O14733 1/20 0.43
GMNN O75496 1/20 0.43
TP53 P04637 1/20 0.43
CYP1A2 P05177 1/20 0.43
HPGD P15428 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15944061 0.89 CDC25A (0.52) IDO1CDC25ACDC25BMAPTTDP1
Aurantiogliocladin SCHEMBL487583 0.77 MAPT (0.50) IDO1CDC25ACDC25BMAPTTDP1
SCHEMBL8368999 0.77 IDO1 (0.44) IDO1CDC25ACDC25BMAPTTDP1
SCHEMBL5589809 0.75 CDC25A (0.44) IDO1CDC25ACDC25BMAPTTDP1
SCHEMBL22882763 0.75 IDO1 (0.44) IDO1CDC25ACDC25BMAPTTDP1
SCHEMBL20193227 0.75 APEX1 (0.42) IDO1CDC25ACDC25BMAPTTDP1
SCHEMBL5455307 0.72 CDC25A (0.48) IDO1CDC25ACDC25BMAPTTDP1
SCHEMBL12957817 0.72 MAOA (0.32) CDC25ACDC25BMAOA
SCHEMBL5590100 0.72 CDC25A (0.32) CDC25ACDC25B
SCHEMBL9655485 0.72 CDC25A (0.64) IDO1CDC25ACDC25BMAPTTDP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11541120-B2 Phosphonium-based ionic drug conjugates ANTHOS PARTNERS, LP (US) 2023-01-03 US disclosed
US-20200353087-A1 PHOSPHONIUM-BASED IONIC DRUG CONJUGATES ANTHOS PARTNERS, LP 2020-11-12 US disclosed
US-9801922-B2 Compositions and methods of treating cancer UNIVERSITY OF IOWA RESEARCH FOUNDATION (US) 2017-10-31 US disclosed
US-20170189447-A1 FORMULATION FOR INCREASING ENERGY NIS Clinical Research (US) 2017-07-06 US disclosed
US-7601877-B2 Condensation of a prenol or isoprenol with a hydroquinone or derivative in the presence of 0.005-1.0 mol percent of a Bronsted or Lewis acid catalyst selected from a bismuth, indium or Group 3 chloride, a heteropolyacid, and an NH- or a CH-acidic compound, oxidizing the ubihydroquinone; improved kinetics DSM IP ASSETS B.V. (NL) 2009-10-13 US disclosed
US-20080275275-A1 Process for the Preparation of Ubihydroquinones and Ubiquinones DSM IPASSETS B.V. (NL) 2008-11-06 US disclosed
WO-2007017168-A1 PROCESS FOR THE PREPARATION OF UBIHYDROQUINONES AND UBIQUINONES DSM IP ASSETS B.V. (NL) 2007-02-15 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20200353087-A1 PHOSPHONIUM-BASED IONIC DRUG CONJUGATES SLC8B1, PHOSPHO1, PBDC1 IDO1 3900/4885CDC25A 3230/4885CDC25B 3503/4885
US-20170189447-A1 FORMULATION FOR INCREASING ENERGY COQ8A, COQ8B, NDUFS6 IDO1 1952/4885CDC25A 822/4885CDC25B 792/4885
US-20080275275-A1 Process for the Preparation of Ubihydroquinones and Ubiquinones UBE2D3, UBE2L3, UBE2I IDO1 3306/4885CDC25A 1584/4885CDC25B 2012/4885
US-11541120-B2 Phosphonium-based ionic drug conjugates SLC8B1, PHOSPHO1, PBDC1 IDO1 3900/4885CDC25A 3230/4885CDC25B 3503/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.